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Background: The prognostic implication of immunophenotyping in acute myeloid leukemia (AML) patients with
NPM1 mutation remains unclear.
Methods: Ninety-four of 543 AML patients diagnosed with NPM1 mutation between 1987 and 2007 were studied.
The expression of surface antigens on leukemic cells was evaluated with respect to clinical manifestations and
outcomes. In order to validate the prognostic effect of the immunophenotypic cluster, another 36 patients with
NPM1 mutation diagnosed between 2008 and 2010 were analyzed.
Results: Ninety-four patients with NPM1 mutations and complete immunophenotyping data were enrolled for a
hierarchical cluster analysis and the result was correlated with clinico-laboratory characteristics. Clustering analysis
divided the patients with NPM1 mutations into the following two groups: group I, CD34(−)/CD7(−), but with
variable expression of HLA-DR; and group II, HLA DR(+)/CD34(+)/CD7(+). With a median follow-up of 53 months,
the group II patients had a significantly shorter relapse-free survival (RFS, median: 3 vs. 23 months, p = 0.006) and
overall survival (OS, median: 11 vs. 40 months, p = 0.02) than group I patients. Multivariate analysis of variables,
including clinico-laboratory data and other gene mutations revealed that the immunophenotypic cluster is an
independent prognostic factor (RFS, p = 0.002; OS, p = 0.024). In order to confirm the prognostic effect of the
immunophenotypic cluster, another 36 patients with NPM1 mutation diagnosed between 2008 and 2010 were
validated. Hierarchical cluster analysis also showed two distinct clusters, group I patient showed significant better
RFS (p = 0.021), and OS (p = 0.055). In total, we stratified 130 NPM1-mutant patients, by FLT3-ITD mutation and
immunophenotypic cluster into distinct prognostic groups (RFS, p < 0.001 and OS, p = 0.017).
Conclusions: Among NPM1-mutated AML, the antigen expression pattern of HLADR(+) CD34(+) CD7(+) is
associated with a poor prognosis, independent to the FLT3-ITD mutation.
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Acute myeloid leukemia (AML) is a heterogeneous group
of diseases characterized by increasing immature progeni-
tors in the bone marrow and peripheral blood. The
leukemic subtypes are crucial to treatment and prognosis.
Immunophenotyping by flow cytometry has been exten-
sively used for the diagnosis and classification of acute* Correspondence: chienyuanchen@ntu.edu.tw; tienhf@ntu.edu.tw
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reproduction in any medium, provided the orleukemia [1,2]. Detection of leukemia-associated immu-
nophenotypes by flow cytometry is also recognized as an
important tool in monitoring minimal residual disease
and predicting clinical outcome [3-5]. Karyotype is an-
other important prognostic factor by which AML patients
can be stratified into good-, intermediate-, and poor-risk
groups. Leukemic blasts in AML with recurrent cytogen-
etic abnormalities, such as t(8;21), t(15;17), and inv(16)
show specific antigen expression patterns [6]. Recently, an
association of CEBPA mutation with a distinct immu-
nophenotype was also reported [7].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2407/13/107About 40%-50% of AML patients have a normal karyo-
type of leukemic cells, and one-half of these patients have
mutations of nucleophosmin (NPM1) [8,9], which en-
codes a shuttle protein transporting continuously between
the nucleus and cytoplasm [10]. NPM1 mutations are
usually associated with absence of HLA-DR and CD34
expression [11]; however, the surface marker expression
in blasts varies in individual AML patients and the clin-
ical implication of immunophenotype in this subtype of
AML remains unclear. Previous reports have suggested
that expression of some surface antigens is correlated
with clinical outcome in AML patients [12-14], but the
prognostic significance of immunophenotype is still an
issue of controversy [15,16]. Most studies analyzed the
prognostic implication of individual antigens, and usually
in a heterogeneous population of AML patients with vari-
ous genetic abnormalities. In this study, we performed a
hierarchical cluster analysis of the immunophenotype
expression profiles in a relatively homogeneous cohort of
AML patients with NPM1 mutations, and correlated the




Five hundred forty-three patients diagnosed as having
de novo AML at the National Taiwan University Hospital
between 1987 and 2007 were recruited in this study as
the investigation cohort. In order to confirm the prog-
nostic implication of the immunophenotypic profile, an-
other 36 AML patients diagnosed with NPM1 mutation
between 2008 and 2010 were enrolled as the validation
cohort. The informed consents were collected from all
living patient. The NPM1 mutation was retrospectively
checked in part of patients. Cryopreserved samples were
collected from marrow bank according to the criteria of
local ethics committee. This research conformed to the
Helsinki Declaration and was approved by the National
Taiwan University Hospital Research Ethics Committee.
Immunophenotype
A panel of monoclonal antibodies, including HLADR, CD2,
CD7, CD11b, CD13, CD14, CD15, CD19, CD33, CD34,
CD41a, and CD56, was used to characterize the phenotypes
of the leukemic cells as previously described [11].
Cytogenetic analysis
Cytogenetic analysis was performed as described previ-
ously [17]. Briefly, the bone marrow and/or peripheral
blood cells were harvested either directly or after 1–3
days of culture. Metaphase chromosomes were banded
by the conventional trypsin-Giemsa banding technique
and karyotyped according to ISCN [18].Gene mutation analysis
Mononuclear cells obtained from bone marrow aspirates
were isolated by Ficoll-Hypaque gradient centrifugation
and cryopreserved. Genomic DNAs were extracted and
amplified by Illustra GenomiPhi V2 DNA amplification
kit as described by the manufacturer (GE Healthcare).
The primer design was according to the previous study
[7,11,19-21]. Analysis of NPM exon 12 mutation was
done as described by Falini et al. [8,11]. Briefly, the final
volume for PCR reaction was 35 μL containing 200 ng
DNA, 200 nmol/L deoxynucleotide triphosphate, 2
mmol/L MgSO4, 140 nmol/L of each primer, and 1 unit
of AmpliTaq Gold polymerase (Applied Biosystems,
Foster City, CA). PCR was done by heating at 95°C for
10 minutes, followed by 35 cycles of 95°C for 45 sec-
onds, 49°C for 1 minute, and 72°C for 1 minute, with a
final step for 10 minutes at 72°C. PCR products were
electrophoresed on 2% agarose gels, purified and
sequenced using the BigDye Terminator v3.1 Cycle
Sequencing kit, which contained AmpliTaq DNA poly-
merase FS (Applied Biosystems), on an automated ABI-
3100 Genetic Analyzer (Applied Biosystems). Abnormal
sequencing results were confirmed by at least two re-
peated analyses. Analysis of the gene mutations of
CEBPA [7], MLL-ITD [19], WT1 [20], FLT3-ITD, FLT3-
TKD, JAK2, PTPN11, NRAS, and KRAS [21] was
performed by polymerase chain reaction and direct
sequencing. Abnormal sequencing results were con-
firmed by at least two repeated analyses.
Statistics
Comparisons between groups were made with the
ANOVA and chi-square tests. Hierarchical cluster analysis
was performed with an agglomeration schedule, and the
cluster distance was expressed as the Binary Square
Euclidean distance [22,23]. A dendrogram was plotted
using the average linkage method. Survival curves were
plotted by the Kaplan-Meier method; differences between
the curves were analyzed by the log-rank test. Multivari-
ate Cox regression analysis was used to investigate inde-
pendent prognostic factors for overall survival and relapse
free survival. All statistical analyses were performed with
SPSS 18.0 for Windows (SPSS, Inc., Chicago, IL, USA).
Values of P < 0.05 were considered significant.
Results
Clinical characteristics of patients with NPM1 gene
mutations
The clinical and laboratory data of the 543 AML pa-
tients are shown in Table 1. There were 315 men and
228 women with a median age of 48 years; 52 patients
were children less than 18 years and 491 were adults.
NPM1 gene mutations were detected in 108 (19.8%) of
AML patients overall, and in 90 (37.5%) of the 241 AML
Table 1 Clinico-laboratory characteristics in AML patients with NPM1 mutations
Total AML patients
(n = 543)
AML patients with NPM1 mutation
(n = 108)




Adult(>18 years) 491 106(21.6) 385(78.4)
Children 52 2(3.8) 50(96.2)
Gender# 0.007
Male 315 50(15.9) 265(84.1)
Female 228 58(25.4) 170(74.6)
Laboratory data
WBC(uL) 20660 38860 14260 0.002
Hemoglobin (g/dL) 8.1 8.4 8.0 0.095
Platelet(uL) 43000 52000 40000 0.865
LDH (units/L) 861 1068 826 0.149
FAB subtype# 0.008
M0 10 0(0) 10(100)
M1 120 23(19.2) 97(80.8)
M2 184 40(21.7) 144(78.3)
M3 40 0(0) 40(100)
M4 131 34(26.0) 97(74.0)
M5 33 10(30.3) 23(69.7)
M6 11 1(9.1) 10(90.9)
M7 3 0(0) 3(100)
Undetermined 5 0(0) 5(100)
Cytogenetic#* <0.001
Normal karyotype 241 90(37.3) 151(62.7)
Abnormal karyotype 283 13(4.6) 270(95.4)
Immunophenotype**
HLA-DR 364/515 50/105(47.6) 314/410(76.6) <0.001
CD7 100/511 16/104(15.4) 84/407(20.6) 0.269
CD13 481/519 96/105(91.4) 385/414(93.0) 0.536
CD14 70/503 18/104(17.3) 52/399(13.0) 0.267
CD15 237/511 46/104(44.2) 191/407(46.9) 0.660
CD33 472/518 105/105(100) 367/413(88.9) <0.001
CD34 328/514 22/104(21.1) 306/410(74.6) <0.001
CD56 109/457 19/95(20.0) 90/362(24.9) 0.347
*Only 524 patients had cytogenetic data.
** Number of patients with positive expression/number of patients studied.
# Number of patients (%).
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http://www.biomedcentral.com/1471-2407/13/107patients with a normal karyotype, which were in agree-
ment to our previous report [11]. NPM1 gene mutations
were rarely detected in children (2/52 (3.8%) in children
vs. 106/491 (21.2%) in adults, p < 0.001). Females had a
higher incidence of NPM1 mutations than males (25.4%
vs. 15.9%, p < 0.001). NPM1 mutations were closely
associated with HLA-DR(−), CD33(+), and CD34(−)
(p < 0.001 for all three markers, Table 1).Hierarchical cluster analysis of immunophenotypes in
patients with NPM1 gene mutations
Hierarchical cluster analysis was performed based on the
expression profile of 8 surface markers (HLADR, CD34,
CD13, CD33, CD7, CD14, CD15, and CD56). The clus-
tering result is displayed by the Treeview dendrogram
(Figure 1). The rows represented individual cases and
the columns were the results of expression of individual
Figure 1 Hierarchical cluster analysis of 94 NPM1- mutated patients.
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http://www.biomedcentral.com/1471-2407/13/107surface markers. The blue color indicates positive ex-
pression and the yellow color indicates negative expres-
sion. Ninety-four patients with NPM1 mutations and
complete immunophenotype data were enrolled in the
hierarchical cluster analysis. The clustering analysis
divided the patients with NPM1 mutations into two
groups, designated as group I (n = 82, 87%; blue color)
and group II (n = 12, 13%; green color), based on the
expression profiles of the immunophenotype (Figure 1).
Leukemic cells from most group I patients were
CD34(−)/CD7(−)/CD13(+)/CD33(+), but with variable
expression of HLA DR and other antigens, while
those from almost all group II patients were HLA
DR(+)/CD34(+)/CD7(+)/CD13(+)/CD33(+); only one
group II patients showed absence of CD34 on leukemic
cells.
Correlation of immunophenotypic cluster with clinico-
laboratory features, associated gene mutations, and
clinical outcome
The clinico-laboratory characteristics of groups I and II
are shown in Table 2. Group II patients had a higher
platelet count than group I patients (P < 0.001), but therewere no other differences in parameters between the
two groups. We determined 11 other gene mutations, in-
cluding FLT3-ITD, FLT3-TKD, CEBPA, MLL-PTD, KIT,
JAK2, PTPN11, WT1, NRAS, and KRAS mutations in
patients with NPM1 mutations. Group II patients had a
higher frequency of FLT3-ITD. There was no associa-
tion between immunophenotypic cluster and other gene
mutations. The COOH-terminal nucleotide changes of
NPM1gene were also checked, but not correlated to the
immunophenotypic cluster.
Ninety-four patients were recruited in cluster analysis
of immunophenotype. There were 31 patients who re-
ceived supportive care alone due to old age and frailty.
Sixty-three patients were treated with standard intensive
chemotherapy of idarubicin 12 mg/m2 per day on days
1–3 and cytarabine 100 mg/m2 per day on days 1–7 and
then 2–4 courses of consolidation chemotherapy with
high-dose cytarabine (2000 mg/m2 q12 h days 1–4, total
8 doses), with or without one anthracycline after
complete remission (CR) was achieved. Eight patients
died following induction chemotherapy, and eleven pa-
tients received HSCT and their disease free survival was
censored at the time of transplantation.
Table 2 Comparison of clinical-laboratory characteristics














WBC(uL) 35710 43580 0.409
Hemoglobin (g/dL) 8.5 8.5 0.710
Platelet(uL) 49000 79000 <0.001












Normal karyotype 67 10
Abnormal karyotype 10 2
Associated gene
mutation*
FLT3-ITD 36(44) 10(83) 0.013
FLT3-TKD 12(15) 1(8) 1.000
NRAS 9(11) 3(25) 0.179
KRAS 0 0 NA
PTPN11 7(9) 0 0.589
KIT 0 0 NA
JAK2 0 0 NA
MLL-PTD 0 0 NA
WT1 2(2) 0 1.000
CEBPA 4(4) 0 1.000
Immunophenotype**
HLA-DR 34(41) 12(100) <0.001
CD7 3(4) 12(100) <0.001
CD13 76(93) 12(100) 1.000
CD14 16(20) 2(17) 1.000
CD15 36(47) 5(42) 1.000
Table 2 Comparison of clinical-laboratory characteristics
between cluster group I and II patients with NPM1
mutated AML# (Continued)
CD33 82(100) 12(100) 1.000
CD34 9(11) 11(92) <0.001
CD56 19(23) 0 0.117
Abbreviation: ITD, internal tandem duplication; TKD, tyrosine kinase domain
mutation; PTD, partial tandem duplication; NA: not application.
# Only 94 patients had complete immunophenotyping data and can be
stratified by clustering analysis.
* Number of patients (% of patients with this gene mutation in each
cluster group).
**Numbers of patients (% of patients with this antigen expression in each
cluster group).
All four patients with CEBPA mutation were mono-allelic.
Chen et al. BMC Cancer 2013, 13:107 Page 5 of 9
http://www.biomedcentral.com/1471-2407/13/107With a median follow-up time of 53 months, the
group II patients had a significantly shorter relapse-free
survival (RFS; median, 3 vs. 23 months; p = 0.006;
Figure 2) and overall survival (OS; median, 11 vs. 40
months; p = 0.02; Figure 2) than group I patients. For
practicality, we compared the outcome of patients with
positivity for all HLA-DR, CD34, and CD7 (n = 11) with
that of other patients (n = 83); it was also shown that the
former groups had a significantly worse prognosis than
the latter group (RFS, p = 0.006; OS, p = 0.02).
We performed Cox regression multivariate analysis of
variables, including clinico-laboratory data (age, gender,
white blood cell count, hemoglobin level, platelet count,
lactic dehydrogenase level, FAB subtype), cytogene-
tics, gene mutations, and immunophenotypic cluster
(Table 3). The multivariate analysis revealed that immu-
nophenotypic cluster was an independent prognostic
factor (RFS, p < 0.001; OS, p = 0.001) in AML patients
with NPM1 mutations.
Hierarchical cluster analysis and survival analysis in
validation cohort
In order to confirm the above finding of the prognostic
value of immunophenotypic clusters, we collected an-
other cohort of 36 AML patients with NPM1 mutation
diagnosed between 2008 and 2010. This validation co-
hort comprised 21 women and 15 men, with a median
age of 59 years (range 18 to 84). The clinical characteris-
tics were similar between these two cohorts, including
age, gender, white blood cell count, hemoglobin level,
platelet count, and serum lactate dehydrogenase level.
Hierarchical cluster analysis also showed two distinct
clusters. Group I patient showed significant better relapse
free survival (median: 19.5 months vs. 10.5 months,
p = 0.021), and overall survival (median: 32 months vs. 13
months, p = 0.055, Additional file 1: Figure S1). This find-
ing confirmed that NPM1-mutated AML patients of
immunophenotypic cluster group had worse prognosis.
To further evaluate the significance of immunophe-
notypic cluster in the prognostic implication of NPM1-
0.00 25.00 50.00 75.00 100.00 125.00
RFS
0.00 25.00 50.00 75.00 100.00 125.00
OS
Median 23 vs 3 months
P=0.006
















Group II Group II
Figure 2 Kaplan-Meier survival curves of relapse-free survival (RFS, left curve) and overall survival (OS, right curve) of 94 NPM1-
mutated patients stratified by immunophenotypic clustering profile.
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http://www.biomedcentral.com/1471-2407/13/107mutated AML, we incorporated both immunophenotypic
cluster and the status of FLT3-ITD into survival analy-
sis in a total 130 NPM1-mutated patients. Combined
FLT3-ITD and immunophenotypic cluster could stratify
these patients into distinct group (RFS, p < 0.001; OS,
p = 0.017). The Kaplan-Meier survival curves of relapse
free survival and overall survival are shown in Figure 3.
Discussion
Immunophenotype analysis is highly helpful for the diag-
nosis and monitoring of minimal residual disease in
hematologic malignancies [3-5]. Though leukemic blasts
from NPM1-mutated AML usually show a specific
immunophenotype with expression of CD13 and CD33
but absence of CD34 and HLA-DR [11], different ex-
pression patterns of surface markers on leukemic cells





Elderly(Age > 60 year) 0.015
Gender (Male vs Female) 0.558
Immunophenotypic cluster (Group II vs Group I) <0.001




Cytogenetic* (Normokaryotype vs Additional changes) 0.597
CEBPA mutation (mutant vs wild type) 0.982
FLT3-ITD (mutant vs wild type) <0.001
FLT3-TKD (mutant vs wild type) 0.191
NA, not applicable, Cytogenetics*: The cytogenetic data includes 91 patients with n
no mitosis.cohort study, hierarchical cluster analysis revealed two
distinct immunophenotypic clusters in NPM1-mutated
patients. Most patients in group I showed CD7(−) CD33
(+) CD34(−), while almost all patients in group II
expressed HLA-DR, CD7, CD33, and CD34 on leukemic
cells. The patients in immunophenotypic cluster group
II had poorer outcomes than cluster group I, and the
immunophenotypic cluster was an independent prog-
nostic factor.
Some AML subtypes showed specific immuno-
phenotypic patterns of leukemic cells, such as coe-
xpression of CD15, CD34 and sometimes, CD19 in
AML with t(8;21); coexpression of CD13, CD33 in ab-
sence of CD34 and HLA-DR in AML with t(15;17) [4-6];
and coexpression of CD34, HLA-DR, CD15 and CD7 in
AML with CEBPA mutation [7]. The prognostic implica-
tion of immunophenotype in AML remains controversialPM1-mutated patients
dd Ratio 95% CI Overall
survival (OS)
p-value
Odd Ratio 95% CI
0.933 0.056-15.647 0.629 NA NA
NA NA 0.871 NA NA
2.190 0.363-13.219 0.001 10.435 1.217-89.461
NA NA 0.898 NA NA
NA NA 0.349 NA NA
NA NA 0.237 NA NA
NA NA 0.942 NA NA
NA NA 0.464 NA NA
NA NA 0.309 NA NA
2.243 0.798-6.306 0.387 NA NA
NA NA 0.135 NA NA
ormal karyotype, 12 patients with additional changes, and 5 patients showed
Figure 3 Kaplan-Meier survival curves of relapse-free survival (left) of all 130 NPM1- mutated patients stratified by immunophenotypic
clustering profile and FLT3 ITD mutation. (p < 0.001). Kaplan-Meier survival curves of overall survival (right) of all 130 NPM1- mutated patients
stratified by immunophenotypic clustering profile and FLT3 ITD mutation. (p = 0.017).
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CD34 expression has been reported in some studies
[25,26], but not in others [27,28]. The same is also true
for CD7 expression. Most studies analyzed the correlation
of the expression of a single marker with clinico-
laboratory characteristics in a rather heterogeneous group
of AML patients. In this study, the immunophenotypic
cluster profiles were analyzed in a relatively homogeneous
population of AML patients. Immunophenotypic cluster
profiles provided distinct prognostic information in
NPM1-mutated AML patients.
There are several large studies of NPM1 mutation in
AML; the presence of FLT3-ITD is shown to be a poor
prognostic factor in NPM1-mutated patients [29,30]. In
order to clarify the association of the immunophenotypic
patterns of NPM1-mutated AML with other gene muta-
tions in AML, we checked class I (FLT3-ITD, FLT3-
TKD, PTPN11, JAK2, KIT, NRAS, KRAS, and WT1) and
class II gene mutations (CEBPA and MLL-PTD). Al-
though the patients in immunophenotypic cluster group
II had a higher incidence of FLT3-ITD, a mutation asso-
ciated with poor prognosis [31], Cox regression multi-
variate analysis revealed that the immunophenotypic
cluster was an independent prognostic factor (RFS,
p < 0.001; OS, p = 0.001) in AML patients with NPM1
mutations. To further evaluate whether the data of flow
cytometry could be directly applied for prognostic pre-
diction in clinical practice, we compared the survival
between the patients with expression of all HLA-DR,
CD34 and CD7 on leukemic cells and other patients.
We found that positivity of all three markers was associ-
ated with shorter RFS and OS (p = 0.006 and 0.02,respectively). So, it may be worthwhile to use the expres-
sion pattern of these three antigens obtained from flow
cytometry to predict the survival of patients at diagnosis.
Immunophenotypic cluster in NPM1-mutated AML
patients has not been described before. In order
to confirm the prognostic effect of the immuno-
phenotypic cluster, we validated the correlation of
immunophenotypic cluster and clinical outcome in an-
other cohort of 36 NPM1-mutated patients diagnosed
between 2008 and 2010. Hierarchical cluster analysis
also showed two distinct clusters, group I patient
showed significant better RFS (median: 19.5 vs. 10.5
months, p = 0.021) and OS (median: 32 months vs. 13
months, p = 0.055). This study was limited to a sin-
gle university hospital, so the prognostic effect of
immunophenotypic cluster should be further validated.
Recently, IDH1, IDH2 and DNMT3A mutations have
also been reported in AML patients with NPM1 muta-
tion [32-34]. Correlating the immunophenotypic cluster
with new biomarkers may also provide more insight into
the molecular mechanisms of leukemogenesis in the
future.Conclusions
In summary, hierarchical cluster analysis of the immu-
nophenotypic profile was able to separate AML patients
with NPM1 gene mutations into two distinct groups
with different prognosis. The immunophenotypic cluster
with HLA-DR(+) CD34(+) CD7(+) is a poor prognostic
factor independent of FLT3-ITD in AML patients with
NPM1 mutations.
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